Mike Boken, Shire
S
Mike Boken
Senior Director of Marketing, Vyvanse, Shire
BIG DEAL: Launching Prevnar, the first blockbuster vaccine
SUCCESS IS: 1 million Vyvanse scripts written 10 months after launch
You have to find a way to make your drug stand out from everybody else," says Mike Boken. He speaks from experience: Standing 7 feet tall, he never gets lost in the crowd.
Mike Boken
There's another truism that Boken lives by. As one of nine brothers and sisters, his mother expected chores to be done right—or else. "What I remember is that if you do it right the first time, you'll be in a better place."
Boken has applied that philosophy to promotion of Adderall XR and its ADHD follow up Vyvanse by developing smart adherence programs that keep patients on drug the first time around. It turns out that what's best for the patient is also best for the company: "We've seen the best ROIs coming from those retention programs."
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
